MAP2K7 and Miyoshi myopathy: The positioning of the GADD45β/MKK7 survival module downstream in the NF-κB pathway further confers additional clinical advantages on DTP3, including its capacity to bypass MM-cell resistance to conventional anti-MM therapies, including proteasome inhibitors, IMiDs and steroids [11,[13], [14], [15]].